Prevalence of Mendelian kidney disease among patients with high-risk APOL1 genotypes undergoing commercial genetic testing in the United States
Francisco, R. d. S.; Punj, S.; Vincent, L.; Sanapareddy, N.; Bhalla, V.; Chertow, G. M.; Keen-Kim, D.; Charu, V.
Show abstract
BackgroundAmong individuals with high-risk APOL1 genotypes, the lifetime risk of developing kidney failure is [~]15%, indicating that other genetic variants or non-genetic modifiers likely contribute substantially to an individual patients risk of progressive kidney disease. Here we estimate the prevalence and distribution of molecularly diagnosed Mendelian kidney diseases among patients with high-risk APOL1 genotypes undergoing commercial genetic testing in the United States. MethodsWe analyzed clinical exome sequencing data from 15,181 individuals undergoing commercial genetic testing for Mendelian kidney disease in the United States from 2020-2021. We identified patients with high-risk APOL1 genotypes by the presence of G1/G1, G1/G2, or G2/G2 alleles. Patients carrying single risk APOL1 alleles were identified as G1/G0, G2/G0; the remainder of patients were G0/G0. We estimated the prevalence and distribution of molecularly diagnosed Mendelian kidney disease stratified by APOL1 genotype. ResultsOf 15,181 patients, 3119 had genetic testing results consistent with a molecular diagnosis of Mendelian kidney disease (20.5%). 1035 (6.8%) had high-risk APOL1 genotypes. The prevalence of molecularly diagnosed Mendelian kidney diseases was lower in individuals with high-risk APOL1 genotypes (9.2%; n=95/1035) compared to single risk APOL1 allele carriers (14.4%; n=243/1687) and those with G0/G0 APOL1 genotypes (22.3%; n=2781/12459). The distribution of molecularly diagnosed Mendelian kidney diseases was broadly similar among patients with and without high-risk APOL1 genotypes. ConclusionsAmong patients undergoing clinical genetic testing, we found a relatively high rate of molecularly diagnosed Mendelian kidney disease in patients with high-risk APOL1 genotypes. Mendelian kidney disease may contribute to wide variation in rates of progression observed among patients with high-risk APOL1 genotypes.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- HBA Copy Number and Kidney Disease Risk among Black Americans: a Longitudinal Cohort Study 96%
- Clonal hematopoiesis of indeterminate potential contributes to accelerated chronic kidney disease progression 94%
- Clonal hematopoiesis of indeterminate potential is associated with worse kidney function and anemia in a cohort of patients with advanced chronic kidney disease 94%
Similar papers in this journal
- Circulating Plasma Biomarkers in Biopsy-Confirmed Kidney Disease: Results from the Boston Kidney Biopsy Cohort 95%
- Impaired incretin homeostasis in non-diabetic moderate-severe CKD 92%
- Comparison of low eGFR prevalence and prediction for mortality using 2009 and 2021 CKD-EPI equations in Mexican adults 90%
Similar papers in this journal
- Recipient APOL1 risk alleles associate with death-censored renal allograft survival and rejection episodes 93%
- Renal tubule Cpt1a overexpression protects from kidney fibrosis by restoring mitochondrial homeostasis 92%
- Post-ischemic inactivation of HIF prolyl hydroxylases in endothelium promotes maladaptive kidney repair by inducing glycolysis 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.